Drugs / PLD
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06687070 | Dec 2024 → May 2026 overdue | carcinoma | Ascentage Pharma Group Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PLD | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06687070 ↗ |
| Route | Other | “Injected on the first day of each cycle, every 28 days as a cycle.” NCT06687070 ↗ |